CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 123 filers reported holding CLOVIS ONCOLOGY INC in Q2 2016. The put-call ratio across all filers is 1.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $87,000 | +47.5% | 12,322 | 0.0% | 0.01% | +33.3% |
| Q4 2020 | $59,000 | -18.1% | 12,322 | 0.0% | 0.01% | -18.2% |
| Q3 2020 | $72,000 | -13.3% | 12,322 | 0.0% | 0.01% | -21.4% |
| Q2 2020 | $83,000 | +6.4% | 12,322 | 0.0% | 0.01% | 0.0% |
| Q1 2020 | $78,000 | -39.1% | 12,322 | 0.0% | 0.01% | -17.6% |
| Q4 2019 | $128,000 | -84.4% | 12,322 | -94.1% | 0.02% | -85.6% |
| Q3 2019 | $818,000 | +67.3% | 208,093 | +717.4% | 0.12% | +84.4% |
| Q1 2016 | $489,000 | -44.6% | 25,459 | +1.0% | 0.06% | -56.5% |
| Q4 2015 | $882,000 | – | 25,209 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |